Skip to main content
SpringerLink
Log in

The Political Economy of Pharmaceutical Production in Brazil

  • Chapter
The New Political Economy of Pharmaceuticals

Part of the book series: International Political Economy Series ((IPES))

Abstract

Over the last two decades global pharmaceutical production has been shaped by a series of profound political, legal and economic changes.1 On the one hand, the rise of bulk pharmaceutical production in Asia and a wave of mergers and acquisitions throughout the 1990s (Kesic, 2009; Nolan, 2001) has resulted in sector concentration (Abbott and Dukes, 2009; ‘t Hoen, 2009). On the other hand, industry consolidation has been compounded by increasing standardization of intellectual property law. One hundred and fifty-three countries now adhere to the World Trade Organization’s (WTO) Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). The Agreement’s standard for intellectual property rights (IPR) has been implemented in most developing countries, with significant implications for diffusion of innovation and the range of public health policy options available to local governments. As these global processes have been under way, nation-states have grappled with how to apply new international standards, create fair domestic regulatory frameworks that maintain sufficient levels of competition in the pharmaceutical sector, and ensure access to medicine for their citizens.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abbott, M. F. and G. Dukes (2009) Global Pharmaceutical Policy (London and New York: Edward Elgar).

    Book  Google Scholar 

  • Almeida, E. N. D. (2009) ‘Analise do trabalho de qualificação de fornecedores de insumos farmacêuticos na unidade de Farmanguinhos’, Masters Thesis in Public Health, FIOCRUZ, Rio de Janeiro, Brazil.

    Google Scholar 

  • Amann, E. (2000) Economic Liberalisation and Industrial Performance in Brazil (New York: Oxford University Press).

    Google Scholar 

  • Amin, T. (2010) ‘Re-visiting the Patents and Access to Medicines Dichotomy: An Evaluation of TRIPs Implementation and Public Health Safeguards in Developing Countries’. In Yu, O. Aginam and J. Harrington (eds) Global Governance of HIV/AIDS: Intellectual Property and Access to Essential Medicines (London: Edward Elgar).

    Google Scholar 

  • ANVISA, (2009) ‘Medicamentos Genéricos.’ July, http://portal.anvisa.gov.br/wps/ content/Anvisa + Portal/Anvisa/Inicio/Medicamentos/Assunto + de + Interesse/Medicamentos + genericos/wps/%20content/Anvisa%E2%80%89+%E2%80%89Portal/Anvisa/Inicio/Medicamentos/Assunto%E2%80%89+%E2%80%89de%E2%80%89+%E2%80%89Interesse/Medicamentos%E2%80%89+%E2%80%89genericos, accessed September 2012.

  • Associação Brasileira Interdisciplinar de Aids (2009) ‘Perguntas e respostas sobre patentes pipeline: Como afetam sua saúde’, Policy paper (Rio de Janeiro ABIA).

    Google Scholar 

  • Azevedo, R. (2010). ‘Brasil ataca acordo de ricos contra falsificação’, Estadão line, http://www.estadao.com.br/noticias/impresso,brasil-ataca-acordo-de-ricos-contrafalsificacao, 621618,0.htm/noticias/impresso,brasil-ataca-acordo-de-ricos-contrafalsificacao,%20621618,0.htm, date accessed 10 November 2010.

  • Barbosa, D. (2009) ‘O papel da ANVISA na concessão de patentes’,http://denisbarbosa.addr.com/papelanvisa.pdf, date accessed 3 December 2010.

  • Basso, M., B. Edson, J. Rodriguez (2011) Intellectual Property Law in Brazil (The Netherlands: Kluwer Law International).

    Google Scholar 

  • Bezerra, C. A. (2006) GeneralManager of Medicines, ANVISA, Personal interview, Brasilia, 24 June.

    Google Scholar 

  • Bird, R. (2009) ‘Developing Nations and the Compulsory Licence: Maximizing Access to Essential Medicines While Minimizing Investment Side Effects’, Journal of Law, Medicine and Ethics, 37: 209–21.

    Article  Google Scholar 

  • Blatt, C. R, S. C Trauthman, E. H. Schmidt, S. Marchesan, L. M. da Silva, and J. L. Martins (2012) ‘Conhecimento Popular e Utilização dos Medicamentos Genéricos na População do Município de Tubarão, SC, Ciênc. saúde coletiva, 17: 79–87.

    Article  Google Scholar 

  • Cassier, M. and C. M. Correa (2003) ‘Patents, Innovation and Public Health: Brazilian Public-Sector Laboratories’ Experience in Copying AIDS Drugs’ in J.-P. Moattli, B. Coriat, Y. Soutryran, T. Barnett, J. Dumoulin and V.-A. Fiori (eds) Economics of AIDS and Access to HIV/AIDS Care in Developing Countries, Issues and Challenges (Paris: Agence Nationale de Recherches sur le Sida).

    Google Scholar 

  • Chakraborty, S. and A. Singhvi (2009) ‘Compulsory Licensing for Access to Medicines in the Developing World’, International Journal of Intellectual Property Management, 3, 110–26.

    Article  Google Scholar 

  • Chequer, P. (2005) ‘Access to Treatment and Prevention: Brazil and Beyond’, Power point presentation to the International Aids Society 2005 Conference, Rio de Janeiro, http://www.aids.gov.br/en/publicacao/access-treatment-and-preventionbrazil-and-beyond/en/publicacao/access-treatment-and-preventionbrazil-and-beyond, accessed 12 December 2011.

  • Correa, M. C. (2000) Intellectual Property Rights, the WTO and Developing Countries: The TRIPS Agreement and Policy Options (London: Zed Books).

    Google Scholar 

  • Correa, M. C. (2011) ‘Pharmaceutical Innovation, Incremental Patenting and Compulsory Licensing’, South Centre Research Paper, 41.

    Google Scholar 

  • Drahos, P. (2008) ‘Does Dialogue Make a Difference? Structural Change and the Limits of Framing’, The Yale Law Journal, Pocket Part 117, 268–73.

    Google Scholar 

  • Gomes, L. (2006) ‘Manager of Foreign Trade’, Febrafarma, personal interview, Sao Pablo, 6 June.

    Google Scholar 

  • González, C. P. V., J. F. Fitzgerald and J. A. Z. Bermúdez (2006). ‘Definición de medicamento genèrico ¿un fin o un medio? Análasis de la regulación en 14 países de la Región de las Américas’, Pan American Journal of Public Health, 20, 314–23.

    Article  Google Scholar 

  • IMS Health (2010) Pharmerging Shake-up: New Imperatives in a RedefinedWorld (Norwalk, CT: IMS Health Incorporated).

    Google Scholar 

  • Jaguaribe, R. (2005) Comments at the International Seminar on Contributions to the Development Agenda on Intellectual Property Rights, Maastricht, The Netherlands, 23–24 September. Confirmed in correspondence with author 18 December 2007.

    Google Scholar 

  • Jawara, F. and A. Kwa (2003) Behind the Scenes at the WTO (London: Zed Books).

    Google Scholar 

  • Jorge, F. M. (2004) ‘TRIPS-plus Provisions in Trade Agreements and Their Potential Adverse Effects on Public Health’, Journal of Generic Medicines, 1, 199–211.

    Article  Google Scholar 

  • Kesic, D. (2009) ‘Strategic Analysis of the World Pharmaceutical Industry’, Management, 14, 59–76.

    Google Scholar 

  • Lustig, N. and I. F. Lopez-Calva (2010) Declining Inequality in Latin America: A Decade of Progress? (Washington, DC: Brookings Institution Press and UNDP).

    Google Scholar 

  • Lybecker, M. K. and E. Fowler (2009) ‘Compulsory Licensing in Canada and Thailand: Comparing Regimes to Ensure Legitimate Use of WTO Rules’, The Journal of Law, Medicine and Ethics, 37, 222–39.

    Article  Google Scholar 

  • Moreira, M. M. (1990) ‘The Point of View of an Emerging Trading Nation: Brazil’ in J. Bhagwati and H. T. Patrick (eds) Aggressive Unilateralism: America’s 301 Trade Policy and the World Trading System (Ann Arbor: University of Michigan Press).

    Google Scholar 

  • Nolan, P. (2001) China and the Global Business Revolution (London: Palgrave).

    Book  Google Scholar 

  • Nolan, P., D. Sutherland and J. Zhang (2002) ‘The Challenge of the Global Business Revolution’, Contributions to Political Economy, 21, 91–110.

    Article  Google Scholar 

  • Nunn, S. A., E. M. D. Fonseca, F. Bastos and S. Gruskin (2009) ‘AIDS Treatment in Brazil: Impacts and Challenge’, Health Affairs, 28, 1103–13.

    Article  Google Scholar 

  • Oliveira, A. M., J. A. Z. Bermudez, G. C. Chaves and G. Velasquez (2004) ‘Has the Implementation of the TRIPS Agreement in Latin America and the Caribbean Produced Intellectual Property Legislation that Favors Public Health?’, Bulletin of the World Health Organization, 82, 811–90.

    Google Scholar 

  • Oliveira, N. B. D. (2006) Vice President of ABIFINA, personal interview, Rio de Janeiro, 26 June.

    Google Scholar 

  • Orsi, L. F., B. Hasenclever, B. Fialho, P. Tigre and B. Coriat (2003) ‘Intellectual Property Right, Anti-AIDS Policy and Generic Drugs: Lessons from the Brazilian Public Health Program’ in J.-P. Moattli, B. Coriate, Y. Soutryran, T. Barnett, J. Dumoulin and V.-A. Fiori (eds) Economics of AIDS and Access to HIV/AIDS Care in Developing Countries, Issues and Challenges (Paris: Agence Nationale de Recherches sur le Sida).

    Google Scholar 

  • Packenham, R. (1994) ‘The Politics of Economic Liberalization: Argentina and Brazil in Comparative Perspective’, Working Paper 206, Kellogg Institute for International Studies.

    Google Scholar 

  • Presidencia da Republica (1993) Lei N°8.666 de Junho de 1993, Codigo Civil, http://www.planalto.gov.br/ccivil_03/Leis/L8666cons.htm, date accessed 10 December 2011.

  • Quental, C., J. Abreu, J. Bomtempo and C. Gadelha (2008) ‘Medicamentos genéricos no Brasil: impactos das políticas públicas sobre a indústria nacional’, Ciencia e Saúde Coletiva, 13, 619–28.

    Article  Google Scholar 

  • Roffe, P. (2004) ‘Bilateral Agreements and a TRIPS-plus World: the Chile–USA Free Trade Agreement. QIAP’,http://www.quno.org/geneva/pdf/economic/Issues/Bilateral-Agreements-and-TRIPS-plus-English.pdf/geneva/pdf/economic/Issues/Bilateral-Agreements-and-TRIPS-plus-English.pdf, date accessed 12 December 2011.

  • Sell, S. (1995) ‘Intellectua1 Property Protection and Antitrust in the DevelopingWorld: Crisis, Coercion and Choice’, International Organization, 49, 315–50.

    Article  Google Scholar 

  • Sell, S. (1998) Power and Ideas: North-Politics of Intellectual Property and Antitrust (Albany, NY: State University of New York Press).

    Google Scholar 

  • Sweet, C. (2008) Indian Multinationals in Brazil: Emerging Multinationals in Emerging Markets. ‘Emerging Multinationals’: Outward Foreign Direct Investment from Emerging and Developing Economies (Copenhagen: Copenhagen Business School).

    Google Scholar 

  • ‘t Hoen, E. (2009) The Global Politics of Pharmaceutical Monopoly Power (Diemen, the Netherlands: AMB Publishers).

    Google Scholar 

  • Tigre, P., J. E. Cassiolato, M. H. D. S. Szapiro and J. C. Ferraz (2002) ‘Institutional Change and Technology: Impacts of Deregulation on the National Innovation System’ in R. Bauman (ed.) Brazil in the 1990s: An Economy in Transition (Basingstoke:Palgrave).

    Google Scholar 

  • Valente, V. (2006) ‘Generics in Latin America: An Analysis of the Brazilian Experience’, Journal of Generic Medicines, 4, 30–6.

    Article  Google Scholar 

  • Vara Federal do Rio Janeiro (2004) Ação ordinária n°2004.51.01.506840–0–37a

    Google Scholar 

  • Vaughan, V. S. (2001) ‘Compulsory Licensing of Pharmaceuticals under TRIPS: What Standard of Compensation?’ Hastings International and Comparative Law Review, 25, 87–110.

    Google Scholar 

  • Vijay, B. (2006) Country Manager, Wockhardt, personal interview, Sao Paulo, 18 May.

    Google Scholar 

  • Vosgerau, M. Z., R. K. T. de Souza, and D. A. Soares. (2011) ‘Utilização de Genéricos em área de Atuação da Equipe de Saúde da Família em Município do Sul do Brasil’, Revista Brasileira de Epidemiologia, 14, 253–63.

    Article  Google Scholar 

  • Weyland, K. (1993) ‘The Rise and Fall of President Collor and Its Impact on Brazilian Democracy’, Journal of Interamerican Studies and World Affairs, 35(1), 1–37.

    Article  Google Scholar 

  • World Bank (2009) Brazil at a Glance. Development Economics LDB Database (Washington, DC: World Bank).

    Google Scholar 

  • Yee, A. and J. Leahy (2008) ‘Shock in India over Ranbaxy Sale’, Financial Times, 11 June.

    Google Scholar 

Download references

Authors
  1. Cassandra M. Sweet
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Humanities and Social Sciences, Deakin University, Australia

    Hans Löfgren (Associate Professor) (Associate Professor)

  2. Centre for Health and International Relations, Aberystwyth University, UK

    Owain David Williams (Research Fellow) (Research Fellow)

Copyright information

© 2013 Cassandra M. Sweet

About this chapter

Cite this chapter

Sweet, C.M. (2013). The Political Economy of Pharmaceutical Production in Brazil. In: Löfgren, H., Williams, O.D. (eds) The New Political Economy of Pharmaceuticals. International Political Economy Series. Palgrave Macmillan, London. https://doi.org/10.1057/9781137315854_2

Download citation

Publish with us

Policies and ethics

Search

Navigation